Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: Results of a multicenter historical cohort study

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1781-1790

  Iwai, Kazuro ^a,b,c   Soejima, Kenzo ^a,d   Kudoh, Shoji ^a,c   Umezato, Yoshimasa ^a,e   Kaneko, Toru ^a   Yoshimori, Kouji ^a,c   Tokuda, Hitoshi ^a,f   Yamaguchi, Tetsuo ^a,g   Mizoo, Akira ^a,h   Setoguchi, Yasuhiro ^a,i   Kamigaki, Takashi ^b   Fujimoto, Katsunada ^b   Goto, Shigenori ^a,b  

^a Lung Cancer Immunotherapy Evaluation Group (LITEG)   (Japan)

^b Seta Clinic Group   (Japan)

^c Japan Anti Tuberculosis Association   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e NIHON UNIVERSITY   (Japan)

^f Social Insurance Chuo General Hospital   (Japan)

^g JR Central Consultants   (Japan)

^h TOKYO KOSEI NENKIN HOSPITAL   (Japan)

ⁱ TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Additive effect; Adoptive immunotherapy; Advanced lung cancer; Overall survival; Performance status; T lymphocyte

Indexed keywords

CD3 ANTIBODY; GEFITINIB; INTERLEUKIN 2; PLATINUM DERIVATIVE; TUMOR MARKER;

ADOPTIVE ACTIVATED T LYMPHOCYTE IMMUNOTHERAPY; ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; EX VIVO STUDY; FEMALE; FOLLOW UP; GENDER; HISTOLOGY; HUMAN; HUMAN CELL; JAPAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; TELECONSULTATION;

ADENOCARCINOMA; AGED; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD3; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84867573369     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1226-4     Document Type: Article

References (41)

1. Rosenberg SA (1984) Immunotherapy of cancer by systemic administration of lymphoid cell plus interleukin-2. J Biol Resp Modif 3:501-511
2. Rosenberg SA, Lotse MT, Muul LM, Vetto JT et al (1986) A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-Activated cells and recombinant interleukin-2. Surgery 100:262-272
3. Grim EA, Mazumder A, Zhang H, Rosenberg SA (1982) Lymphnokine- activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2-Activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823-1841
4. Hefeneider SH, Conlon PJ, Henney CS, Gllis S (1983) In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident killer cells. J Immunol 130:222-227
5. Rosenberg SA (1984) Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J. Biol Response Modif 3:501-511
6. Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA (1984) The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol 132:2123-2128
7. Mulé JJ, Shu S, Schwartz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastasis with LAK cells and recombinant interleukin-2. Science 28:1487-1489
8. Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of murine experimental hepatic metastases with lymphokineactivated killer cells and recombinant interleukin 2. Cancer Res 45:3735-3741
9. Mulé JJ, Yang J, Shu S, Rosenberg SA (1986) The anti-tumor efficacy of lymphokine-Activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastasis and cytolytic activity of lymphokine-Activated killer cells. J Immuol 136:3899-3909
10. Ettinghausen SE, Rosenberg SA (1986) Immunotherapy of murine sarcomas using lymphokine activated killer cells: Optimization of the schedule and rout of adminstration of recombinant interleukin-2. Cancer Res 46:2784-2792
11. Lee K-e, O'Donnell W, Cockett ATK (1988) Ineffectiveness of adoptive chemoinnumotherapy with lymphokine-Activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murin bladder cancer. J Biol Response Modif 7:43-53
12. Yoshimori K (1992) A study to increase the therapeutic effects of adoptive immunotherapy in vivo influence on the generation of lymphokine-Activated killer (LAK) cells and therapeutic effects of LAK cells with antitumor drug (cyclophosphamide). Arch Nippon Med Sch 59:418-426
13. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP et al (1987) A progress report of the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889-897
14. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE et al (1993) Prospective randomized trial of high dose interleukin-2 alone or in conjugation with lymphokine- activated killer cell for treatment of advanced cancer. J Natl Cancer Inst 85:622-632
15. Rosenberg SA, Yang JC, Restifo NP (2005) Cancer immunotherapy: moving beyond current vaccines. Nat Med 9:909-914
16. Bringle L, Brown NJ, Lewis CE (2002) The role of tumorassociated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 196:254-265
17. Pollard JW (2004) Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer 4:71-78
18. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH et al (2006) Targeting tumor-Associated macrophages as a novel strategy against breast cancer. J Clin Invest 116:2132-2141
19. Powell DJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA (2006) Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177:6527-6539
20. Sangha R, Butts C (2007) L-BLP25: a peptide vaccine strategy in non-small cell lung cancer. Clin Cancer Res 13:4652-4654
21. Kuemmel A, Single K, Bittinger F, Faldum A, Schmidt LH et al (2009) TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer 63:98-105
22. Wilhelm M, Kunzman V, Eckstain S, Reimer P, Weissinger F et al (2003) Gamma-delta T cells for immune therapy of patients with lymphoid malignancies. Blood 102:200-206
23. Liu Z, Eltoum I-EA, Guo B, Beck BH, Cloud GA, Lopez RD (2008) Protective immunosurveillance and therapeutic antitumor activity of gamma-delta T cells demonstrated in a mouse model of prostate cancer. J Immunol 180:6044-6053
24. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I et al (2008) Phase-I study of Innacell gamma deltaTM, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57:1599-1609
25. Abe Y, Muto M, Nixed M, Nakagawa Y, Nicol A et al (2009) Clinical and immunological evaluation of zoledronate-Activated Vgamma9-gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 37:956-968
26. Kimura H, Yamaguchi Y (1997) A phase III randomized study of interleukin-2 lymphokine-Activated killer cell immunotherapy combined with chemotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80:42-49
27. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T et al (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 356:802-807
28. Egawa K (2004) On the safety assurance of cell processing carried out in medical institutions for autologous immune-cell therapy. Hum Cell 17:1-6
29. Egawa K (2004) Immuno-cell therapy of cancer in Japan (review). Anticancer Res 24:3321-3326
30. Goto S, Kaneko T, Miyamoto Y, Eriguchi M, Kato A et al (2005) Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma. Anticancer Res 25:3741-3745
31. Kaneko T, Goto S, Kato A, Akeyama T, Tomonaga M et al (2005) Efficacy of immune-cell therapy in patients with advanced pancreatic cancer. Anticancer Res 25:3709-3714
32. Goto S, Noguchi A, Jinguji H, Takahara M (2006) The therapeutic potential of immune-cell therapy of cancer in combination with aminobisphophonates. Anticancer Res 26:3989-3996
33. Hyde L, Wolf J, McCracken S, Yesner R (1970) Natural course of inoperable lung cancer. Chest 64:309-312
34. Woods RL, Williams CJ, Levi J, Page J, Bell D et al (1990) A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61:608-611
35. Helsing M, Bergman B, Thaning L, Hero U (1998) Quality of life and survival in patients with advanced non-small lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomized phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 37:1036-1044
36. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B et al (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcomes. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Caner. Br J Cancer 83:447-453
37. Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ et al (2004) Big Lung Trial participants. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59:828-836
38. Thatcher N, Chang A, Parikh P, Rodrigues Pereira R Jr. et al (2005) Gefinitib plus supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537
39. Shepherd FA, Pereria JR, Ciuleanu T, Tan EH, Hirsh V et al (2005) Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 353:123-132
40. Keller SM, Vangel MG, Adak S, Wagner H, Schiller JH et al (2002) The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stage II and IIIa non-small cell lung cancer. Lung Cancer 37:303-309
41. Japanese Joint Committee for Lung Cancer Registration (2009) A Japanese lung cancer registry study at 2002. Jpn J Lung Cancer 49:975-987